Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 43

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 43
---
 The shares underlying these options vest in equal monthly installments over 48 months commencing on the vesting commencement date, subject to Dr. Gottesdiener’s continuous service relationship with the Company through each applicable vesting date. The stock options are also subject to certain acceleration of vesting provisions as provided in the applicable named executive officer’s employment agreement.

(3) The underlying shares vest in four tranches (consisting of 100,000 shares each) upon the achievement of a pre-determined milestone for each tranche as well as Dr. Gottesdiener’s continuous service relationship with the Company through both the applicable achievement date and the first anniversary of the grant date. The stock options are also subject to certain acceleration of vesting provisions as provided in the applicable named executive officer’s employment agreement. As of December 31, 2024, three of the four tranches have not vested and one of the tranches has satisfied its applicable milestone, but has not yet satisfied the service-based requirement.

(4) The shares underlying these options vest as follows: 25 percent vest on the 1-year anniversary of the vesting commencement date, and 1/48th of the shares vest on a monthly basis thereafter, in each case subject to Dr. Reine’s continuous service relationship with the Company through each applicable vesting date. The stock options are also subject to certain acceleration of vesting provisions as provided in the applicable named executive officer’s employment agreement.

(5) The underlying shares vest in three tranches (consisting of 100,000 shares, 75,000 shares and 75,000 shares) upon the achievement of a pre-determined milestone for each tranche, subject to Dr. Reine’s continuous service relationship with the Company through each applicable vesting date. The stock options are also subject to certain acceleration of vesting provisions as provided in the applicable named executive officer’s employment agreement. As of December 31, 2024, two of the tranches, totaling 175,000 shares, have satisfied their applicable milestones and have vested.

(6) The shares underlying these options vest in equal monthly installments over 48 months commencing on the vesting commencement date, subject to Dr. Duffield’s continuous service relationship with the Company through each applicable vesting date. The stock options are also subject to certain acceleration of vesting provisions as provided in the applicable named executive officer’s employment agreement.

(7) The restricted shares vest as follows: 25 percent vest on the 1-year